Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Less flashy, yet more broadly and immediately applicable, were the studies on food, the other stuff of life beyond our DNA.